Mumps Work Group: Terms of Reference

Objective
• Evaluate and propose policy options to prevent or control mumps outbreaks in the United States

Activities
• Review epidemiology of mumps in the 2-dose vaccine era, including the international experience
• Review available evidence on duration of immunity for mumps after 2 doses of MMR and other risk factors for vaccine failure
• Review available evidence on impact of a 3rd dose of MMR for mumps outbreak control
• Evaluate programmatic implications and cost of various policy options for a 3rd dose of MMR to prevent or control mumps outbreaks
Mumps Work Group: Members

**ACIP**
- Kelly Moore, Chair
- Paul Hunter
- Cynthia Pellegrini
- Jose Romero

**Ex Officio Members & Liaison Representatives**
- Carol Baker (IDSA)
- Chas DeBolt (CSTE)
- Shalini Desai (NACI)
- Susan Even (ACHA)
- Amy Groom (IHS)
- Melissa Martinez (AAFP)
- Dawn Nolt (AAP/COID)
- Steven Rubin (FDA/CBER)
- Jane Zucker (AIM)

**Consultants**
- Huong McLean
- Patricia Quinlisk
- Jane Seward
- Stanley Plotkin*

**CDC**
- Mona Marin, CDC lead
- Tracy Ayers
- Nakia Clemmons
- Carole Hickman
- Manisha Patel
- Paul Rota
- Janell Routh
- Melinda Wharton
- Patricia Wodi
- Fangjun Zhou
- Adria Lee
- Mariel Marlow

*expert consultant on scientific discussions*
Mumps ACIP Work Group Evidence Assessment
March-October 2017

Working Group Members’ Areas of Expertise

- Infectious Diseases
- Mumps
- Immunology
- Vaccine Policy
- Epidemiology Modeling
- Disease Control

Mumps Work Group
20 hrs of calls
4 online surveys

Mumps cases/outbreaks

Published data

Unpublished data

State Health Department
Academia
Federal (CDC, FDA, IHS)
Professional Medical Societies (AAP, AAFP, IDSA)
College Health Association
Consumer Protection

Organizations and Programs Represented

Practices Surveys:
Health Departments/Universities

Data call: Health Departments

Policy Considerations

Opinion Surveys:
Students/Parents
Mumps ACIP WG Evidence Assessment

• Scientific evidence is limited and insufficient at this time to fully characterize the impact of a 3rd dose of MMR vaccine on reducing the size or duration of mumps outbreaks

• WG agrees that there is evidence available for a proposed recommendation to decrease the risk for mumps disease in persons at increased risk because of an outbreak
<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>Dr. Kelly Moore</td>
</tr>
<tr>
<td></td>
<td>ACIP/Tennessee Immunization Program</td>
</tr>
<tr>
<td>Update on mumps epidemiology in the United States, 2017</td>
<td>Dr. Mona Marin, CDC</td>
</tr>
<tr>
<td>GRADE: third dose of MMR vaccine</td>
<td>Dr. Mariel Marlow, CDC</td>
</tr>
<tr>
<td>Considerations and proposed recommendations</td>
<td>Dr. Mona Marin, CDC</td>
</tr>
<tr>
<td>Vote</td>
<td>Dr. Mona Marin, CDC</td>
</tr>
<tr>
<td>VFC vote</td>
<td>Dr. Jeanne Santoli, CDC</td>
</tr>
</tbody>
</table>